---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-007711"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2023-03-24T23:59:59+00:00"
generated_at: "2026-06-17T17:22:22.137586+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GeoVax 2022 net loss $14.0M, cash $27.6M; clinical trials expand

## Summary
- Net loss for 2022 was $14.0M, versus $18.6M in 2021; R&D expenses fell to $9.1M from $15.6M.
- Cash balance at Dec 31, 2022: $27.6M, up from $11.4M in 2021; raised $35.4M from equity and warrant exercises.
- Phase 1/2 trial of Gedeptin® for advanced head & neck cancer expanded to three NCI Cancer Centers.
- GEO-CM04S1 COVID-19 vaccine advancing in two Phase 2 trials; data show robust T cell and antibody responses.

## SEC filing metadata
- accession: 0001437749-23-007711
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2023-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774923007711/0001437749-23-007711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774923007711/govx20230323_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-007711
- JSON: https://secwatch.observer/filing/0001437749-23-007711.json
- Plain text: https://secwatch.observer/filing/0001437749-23-007711.txt

## Key facts
- Earnings Releases
  GeoVax Labs, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: On March 23, 2023, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/832489/000143774923007711/0001437749-23-007711-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.